Want to see ZYME full AI Analyst Report?

Zymeworks (ZYME) Stock Forecast & Price Target

642 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZYME Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Zymeworks

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZYME Stock 12 Month Forecast

Average Price Target

$39.89

▲(74.49% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $39.89 with a high forecast of $51.00 and a low forecast of $32.00. The average price target represents a 74.49% change from the last price of $22.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.888888888888886,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,24.175384615384615,26.410769230769233,28.646153846153847,30.88153846153846,33.11692307692307,35.35230769230769,37.58769230769231,39.823076923076925,42.058461538461536,44.29384615384615,46.529230769230765,48.76461538461538,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,23.32068376068376,24.701367521367523,26.08205128205128,27.46273504273504,28.843418803418803,30.224102564102562,31.604786324786325,32.985470085470084,34.36615384615384,35.7468376068376,37.12752136752137,38.50820512820512,{"y":39.888888888888886,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,22.713846153846156,23.48769230769231,24.261538461538464,25.035384615384615,25.80923076923077,26.583076923076923,27.356923076923078,28.130769230769232,28.904615384615383,29.67846153846154,30.45230769230769,31.226153846153846,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.085,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.17,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.61,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$51.00

Average Price Target$39.89

Lowest Price Target$32.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eva Fortea Verdejo

Wells Fargo

$37→$40

Buy

74.98%

Upside

Reiterated

08/07/26

Wells Fargo Remains a Buy on Zymeworks (ZYME)

Gregory Renza

Truist Financial

$31→$32

Buy

39.98%

Upside

Reiterated

08/07/26

Zymeworks (ZYME) Gets a Buy from Truist Financial

Stephen Willey

Stifel Nicolaus

$47→$46

Buy

101.22%

Upside

Reiterated

08/07/26

Zymeworks price target lowered to $46 from $47 at StifelZymeworks price target lowered to $46 from $47 at Stifel

Charles Zhu

LifeSci Capital

$34

Buy

48.73%

Upside

Reiterated

08/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert Burns

H.C. Wainwright

$46→$51

Buy

123.10%

Upside

Reiterated

08/05/26

Analysts Are Bullish on These Healthcare Stocks: Charles River Labs (CRL), Zymeworks (ZYME)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

$40

Buy

74.98%

Upside

Initiated

07/30/26

Zymeworks (ZYME) Receives a Buy from B. Riley Securities

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$43

Buy

88.10%

Upside

Reiterated

06/30/26

Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)

Yigal Nochomovitz

Citi

$35→$37

Buy

61.85%

Upside

Reiterated

06/30/26

Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37

David Martin PhD

Bloom Burton

$35→$36

Buy

57.48%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

05/08/26

Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward

Jonathan Miller

Evercore ISI

$33→$48

Buy

109.97%

Upside

Reiterated

03/09/26

Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

03/03/26

Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating

Reni Benjamin

Citizens JMP

$32

Buy

39.98%

Upside

Initiated

12/03/25

Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP

Andrew Berens

Leerink Partners

$37→$40

Buy

74.98%

Upside

Reiterated

11/19/25

Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eva Fortea Verdejo

Wells Fargo

$37→$40

Buy

74.98%

Upside

Reiterated

08/07/26

Wells Fargo Remains a Buy on Zymeworks (ZYME)

Gregory Renza

Truist Financial

$31→$32

Buy

39.98%

Upside

Reiterated

08/07/26

Zymeworks (ZYME) Gets a Buy from Truist Financial

Stephen Willey

Stifel Nicolaus

$47→$46

Buy

101.22%

Upside

Reiterated

08/07/26

Zymeworks price target lowered to $46 from $47 at StifelZymeworks price target lowered to $46 from $47 at Stifel

Charles Zhu

LifeSci Capital

$34

Buy

48.73%

Upside

Reiterated

08/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert Burns

H.C. Wainwright

$46→$51

Buy

123.10%

Upside

Reiterated

08/05/26

Analysts Are Bullish on These Healthcare Stocks: Charles River Labs (CRL), Zymeworks (ZYME)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

$40

Buy

74.98%

Upside

Initiated

07/30/26

Zymeworks (ZYME) Receives a Buy from B. Riley Securities

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$43

Buy

88.10%

Upside

Reiterated

06/30/26

Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)

Yigal Nochomovitz

Citi

$35→$37

Buy

61.85%

Upside

Reiterated

06/30/26

Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37

David Martin PhD

Bloom Burton

$35→$36

Buy

57.48%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Taysha Gene Therapies (NASDAQ: TSHA) and Zymeworks (NASDAQ: ZYME)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

05/08/26

Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward

Jonathan Miller

Evercore ISI

$33→$48

Buy

109.97%

Upside

Reiterated

03/09/26

Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

03/03/26

Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating

Reni Benjamin

Citizens JMP

$32

Buy

39.98%

Upside

Initiated

12/03/25

Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP

Andrew Berens

Leerink Partners

$37→$40

Buy

74.98%

Upside

Reiterated

11/19/25

Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zymeworks

3 Months

Yigal NochomovitzCiti

Success Rate

12/16 ratings generated profit

Average Return

+14.67%

Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +14.67% per trade.

1 Year

Yigal NochomovitzCiti

Success Rate

12/16 ratings generated profit

Average Return

+33.86%

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +33.86% per trade.

2 Years

Yigal NochomovitzCiti

Success Rate

13/16 ratings generated profit

Average Return

+65.26%

Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +65.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZYME Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZYME has received 19 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZYME average Analyst price target in the past 3 months is 39.89.

Each month's total comprises the sum of three months' worth of ratings.

ZYME Financial Forecast

ZYME Earnings Forecast

Next quarter’s earnings estimate for ZYME is $2.14 with a range of -$0.71 to $3.39. The previous quarter’s EPS was -$0.62. ZYME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.

ZYME Sales Forecast

Next quarter’s sales forecast for ZYME is $212.33M with a range of $4.00M to $277.00M. The previous quarter’s sales results were $4.59M. ZYME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year ZYME has Performed in-line its overall industry.

ZYME Stock Forecast FAQ

What is ZYME’s average 12-month price target, according to analysts?

Based on analyst ratings, Zymeworks’s 12-month average price target is 39.89.

What is ZYME’s upside potential, based on the analysts’ average price target?

Zymeworks has 74.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZYME a Buy, Sell or Hold?

Zymeworks has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Zymeworks’s price target?

The average price target for Zymeworks is 39.89. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $32.00. The average price target represents 74.49% Increase from the current price of $22.86.

What do analysts say about Zymeworks?

Zymeworks’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ZYME?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zymeworks (ZYME) Stock Forecast & Price Target

ZYME Analyst Ratings

ZYME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zymeworks

ZYME Analyst Recommendation Trends

ZYME Financial Forecast

ZYME Earnings Forecast

ZYME Sales Forecast

ZYME Stock Forecast FAQ

Detailed List of Analyst Forecasts